|
|
|
ChemGenex uses genomics approach to develop new anticancer drug and predict possible side effects
Understanding how genes respond to chemicals in diseased and normal tissues, in both cell cultures and living systems, can help researchers develop new drugs more efficiently. Such knowledge can spotlight drug toxicities, help select dosing regimens for clinical trials, and identify which patients may best benefit from treatment. Researchers from ChemGenex present data showing the use of chemical genomics and informatics in the development of a new cancer therapeutic, now in Phase I/II human testing. ChemGenex Therapeutics Contact:
Joan Kureczka
JKureczka@aol.com
415-821-2413
J. Kureczka Associates
Message posted by: Wouter Kalle
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|